June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure after Intravitreal Triamcinolone Injection
Author Affiliations & Notes
  • Ahmad A Aref
    Illinois Eye & Ear Infirmary, University of Illinois College of Medicine, Chicago, IL
  • Ingrid U Scott
    Ophthalmology, Penn State College of Medicine, Hershey, PA
    Public Health Sciences, Penn State College of Medicine, Hershey, PA
  • Neal Oden
    The EMMES Corporation, Rockville, MD
  • Michael S Ip
    University of Wisconsin, Madison, WI
  • Barbara A Blodi
    University of Wisconsin, Madison, WI
  • Paul C. Van Veldhuisen
    The EMMES Corporation, Rockville, MD
  • Footnotes
    Commercial Relationships Ahmad Aref, None; Ingrid Scott, None; Neal Oden, None; Michael Ip, None; Barbara Blodi, None; Paul Van Veldhuisen, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5813. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ahmad A Aref, Ingrid U Scott, Neal Oden, Michael S Ip, Barbara A Blodi, Paul C. Van Veldhuisen, ; Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure after Intravitreal Triamcinolone Injection. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5813.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Retrospective studies investigating intraocular pressure (IOP) events after intravitreal triamcinolone acetonide injection (IVTA) have reported a wide range of incidence rates. In this study, prospectively gathered data from the Standard of Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study were analyzed to determine incidence, risk factors, and time course of IOP events in patients undergoing IVTA therapy. This will provide guidance for individualized clinical decision-making, follow-up, and patient management.

 
Methods
 

The SCORE Study includes two multicenter phase III randomized clinical trials conducted at 75 clinical sites. Participants with retinal vein occlusion-associated macular edema were randomized to standard of care (SOC), 1-mg IVTA, or 4-mg IVTA therapy. Exclusion criteria: baseline IOP>25 mm Hg, history of intravitreal corticosteroid, history of peribulbar corticosteroid within 6 months, history of open-angle glaucoma or steroid-induced IOP elevation, subsequent diagnosis of neovascular glaucoma, and treatment cross-overs. Kaplan-Meier incidence of IOP events at 36 mos in each of the randomized groups was assessed.

 
Results
 

Six hundred sixteen subjects met the study criteria and were followed for 24.7+10.3 (SD) mos. Kaplan-Meier incidences of IOP events are shown in the Table and Figure. Incidences of IOP>25 mm Hg at 36 mos were 8%, 12%, and 47% in the SOC, 1-mg IVTA, and 4-mg IVTA groups, respectively. Rates were significantly higher for the 4-mg IVTA group compared with the other groups (P<.0001 for IOP rise>25, >30, >10 mm Hg from baseline, and commencement of IOP-lowering medication).Younger age, 4-mg IVTA treatment, and higher baseline IOP were all found to confer greater risk (P<.05 for all). The median number of days from time of 1st injection to IOP>25 mm Hg was 118 and 35 days in participants treated with 1-mg and 4-mg IVTA, respectively.

 
Conclusions
 

In SCORE, risk factors for IOP events included 4-mg IVTA treatment dose, younger age, and higher baseline IOP. Clinicians should be mindful of these factors when assessing risk-benefit of IVTA therapy and also of the need for long-term follow-up of patients at risk for this complication.  

 
Incidences of IOP-Related Events in the SCORE Study.
 
Incidences of IOP-Related Events in the SCORE Study.
 
 
Kaplan-Meier analysis curve depicting rates of IOP>25 mm Hg according to treatment group.
 
Kaplan-Meier analysis curve depicting rates of IOP>25 mm Hg according to treatment group.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×